(Q33400353)

English

Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

pegylated interferon

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Ryosuke Tateishi

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Hayato Nakagawa

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

19

object named as

Kazuhiko Koike

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

Koji Uchino

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Shuntaro Obi

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Shinpei Sato

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Miho Kanda

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Takahisa Sato

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Toru Arano

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Kenichiro Enooku

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Eriko Goto

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Ryota Masuzaki

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Yoshinari Asaoka

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Yuji Kondo

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Noriyo Yamashiki

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Tadashi Goto

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Shuichiro Shiina

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Masao Omata

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Haruhiko Yoshida

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

publication date

22 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

47

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1152-1159

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Cancer incidence and incidence rates in Japan in 2003: based on data from 13 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-α and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Interferon-beta is more potent than interferon-alpha in inhibition of human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Systemic therapy for advanced hepatocellular carcinoma: a review.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

5-Fluorouracil in hepatocellular carcinoma.Report of twenty-one cases

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Phase II study of 5-fluorouracil (5-FU) and high dose folinic acid (HDFA) in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Phase I and pharmacokinetic study of 5-fluorouracil administered by 5-day continuous infusion in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0574-3

21 January 2018

Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan

1 reference

https://pubmed.ncbi.nlm.nih.gov/22438097

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/22438097

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors

1 reference

https://pubmed.ncbi.nlm.nih.gov/22438097

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22438097

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil

1 reference

https://pubmed.ncbi.nlm.nih.gov/22438097

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22438097

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22438097

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22438097

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22438097

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22438097

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22438097

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genes associated with human hepatocellular carcinoma cell chemosensitivity to 5-fluorouracil plus interferon-alpha combination chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22438097

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00535-012-0574-3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438097%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33400353&oldid=1584692161"